ema semaglutide naion label update 2025 Once Again Linked to in Largest Study to Date The European Medicines Agency's (EMA) – Ischemic optic neuropathy with semaglutide:

Semaglutide is typically administered as a weekly injection, and this schedule is crucial for maintaining consistent results

California-specific requirements: Notable: California Medi-Cal will stop covering GLP-1 medications for weight loss effective January 2026 , classifying them as non-covered services (www.cmadocs.org)

Drink at least half a gallon of water daily Observe if you develop any symptoms and inform your healthcare provider if you observe any signs This medication can affect your blood sugar status, so consult with us or your care provider if changes in diet or pills are needed if you have diabetes If you need to start taking a particular medication or program, inform your care team before you do If you notice any changes in your behavior, such as new or worsening feelings of deep sadness, thoughts of harming yourself, anxiety, or other unusual thought patterns, call your care team right away If you think you are pregnant or wish to become pregnant, losing weight is not recommended and may cause harm to the unborn child

However, this effect was not observed in the extended-access paradigm